Gujarat Themis Biosyn Limited (GUJTHEM.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹352.60 (+4.35%) as of
Key statistics
- Market cap
- 45.89B
- P/E (TTM)
- 78.88
- EPS (TTM)
- 4.47
- Dividend yield
- 0.20%
- 52-week range
- 225.05 – 479.00
- Beta
- 0.64
- Revenue (TTM)
- 1.74B
- Profit margin
- 28.02%
- Volume
- 167.63k
About Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.